Flora Growth announced a distribution agreement with Canopy Growth for its Storz & Bickel medical line of vaporizers in Australia through Flora's subsidiary, Australian Vaporizers. This agreement marks an expansion of Flora's footprint in the medical cannabis market in Australia.
Canopy Growth's Storz vaporizers are built with precision for optimal dosing and efficiency, ensuring users receive a consistent and controlled experience.
"Canopy Growth is a market leader with a $400 million market capitalization. We are very much interested in partnering with Canopy Growth to bring their highly regarded Storz vaporizers to the Australian market," said Clifford Starke, Chairman and Chief Executive Officer. "With Australian Vaporizers at the forefront of this initiative, we are confident that our distribution of Canopy's Storz products will further enhance the standard of care for medical cannabis patients in Australia."
Australian Vaporizers, Flora's subsidiary in the Australian market, will spearhead the distribution of Storz vaporizers to healthcare professionals, and clinics across the country. This agreement will enable Flora to meet the growing demand for advanced medical cannabis consumption solutions.
Through this partnership, Flora will also benefit from Canopy Growth's global reputation and expertise in the medical cannabis sector.
